Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-19
    E.g., 2018-08-19

Archive Search

3 results
11:32 AM, Jan 20, 2017  |  BC Week In Review | Company News  |  Deals

APT Therapeutics, AZ deal

The companies partnered to develop APT's APT102 . APT will receive an upfront payment and is …
development milestones. AstraZeneca, which has an option to acquire the product, will fund trials of APT102
to treat heart attack and stroke. APT102, a recombinant form of human apyrase, is in preclinical …
12:00 AM, Sep 11, 2014  |  BC Innovations | Distillery Therapeutics

Indication: Cardiovascular disease

can be broken down by the apyrase activity of ENTPD3. An optimized version of ENTPD3-called APT102-was …
that showed reduced aggregation and increased apyrase activity compared with the natural protein. In vitro, APT102
ADP-dependent human platelet aggregation. In a canine model of thrombotic occlusion of the coronary artery, APT102
12:00 AM, May 10, 2004  |  BioCentury | Finance

Midwest work ethic

will provide about two years of runway and allow it to submit INDs for its APT102